Comparative studies of various hyaluronic acids produced by microbial fermentation for potential topical ophthalmic applications

被引:31
作者
Guillaumie, Fanny [1 ]
Furrer, Pascal [2 ]
Felt-Baeyens, Olivia [2 ]
Fuhlendorff, Birgit L. [1 ]
Nymand, Soren [3 ]
Westh, Peter [3 ]
Gurny, Robert [2 ]
Schwach-Abdellaoui, Khadija [1 ]
机构
[1] Novozymes Biopolymer AS, DK-2880 Bagsvaerd, Denmark
[2] Univ Lausanne, Sch Pharmaceut Sci, Univ Geneva, CH-1211 Geneva 4, Switzerland
[3] Roskilde Univ Ctr, Dept Life Sci & Chem, DK-4000 Roskilde, Denmark
关键词
hyaluronic acid; hyaluronan; topical ophthalmic; ocular; filterability; viscosity; viscoelasticity; precorneal residence time; tolerance; artificial tears; eye drops; contact lens solutions; W/V SODIUM HYALURONATE; DRY EYE SYNDROME; POLYVINYL-ALCOHOL; VEHICLES; RABBITS; DROPS; 0.1-PERCENT; WATER; BIOAVAILABILITY; MULTICENTER;
D O I
10.1002/jbm.a.32481
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
This work presents a comparative Study of various hyaluronic acids (HA) produced by fermentation of either Bacillus subtilis or Streptococcus towards the selection of an optimal molecular weight (MW) HA for the preparation of topical ophthalmic formulations. The influence of HA MW on water binding capacity, sterile filtration, rheological properties, precorneal residence time and Ocular tolerance of ophthalmic Solutions was investigated. Molecular weight did not affect hydration of hyaluronic acid according to differential scanning calorimetry (DSC). In general, medium MW HA (0.6-1 MDa) resulted in solutions that were superior in terms of sterile filtration and kinematic viscosity requirements compared to high MW HA (>1 MDa). Moreover, all HA-based solutions exhibited well-defined viscoelastic properties that depend oil MW. Gamma scintigraphic data indicated that HA MW at 0.1% concentration (w/v) and HA origin did not significantly affect the corneal residence time on rabbit eyes. A 0.3%, solution of high MW HA had a prolonged residence time in the precorneal area compared to a medium MW HA at the same concentration. Finally, an in vivo ocular irritation test based oil confocal laser scanning ophthalmoscopy (CLSO) conclusively showed the excellent tolerance of both Bacillus-derived HA and Streptococcus-derived HA after topical instillation onto the corneal surface. Overall, this comprehensive work highlights the superiority of medium MW hyaluronic acid for topical ophthalmic formulations based oil their physico-chemical and biological properties, tolerance and handling. Such solutions are expected to enhance tear film stability, to allow for maximum comfort, and to exhibit high residence times, while being biocompatible and easy to sterile filter. (C) 2009 Wiley Periodicals, Inc. J Biomed Mater Res 92A: 1,421-1430, 2010
引用
收藏
页码:1421 / 1430
页数:10
相关论文
共 50 条
[1]   The influence of eye solutions on blinking and ocular comfort at rest and during work at video display terminals [J].
Acosta, MC ;
Gallar, J ;
Belmonte, C .
EXPERIMENTAL EYE RESEARCH, 1999, 68 (06) :663-669
[2]  
ALBASINI M, 1995, FARMACO, V50, P633
[3]   NON-FREEZING WATER IN PROTEIN SOLUTIONS [J].
ALI, S ;
BETTELHEIM, FA .
COLLOID AND POLYMER SCIENCE, 1985, 263 (05) :396-398
[4]   Rheological study on hyaluronic acid and its derivative solutions [J].
Ambrosio, L ;
Borzacchiello, A ;
Netti, PA ;
Nicolais, L .
JOURNAL OF MACROMOLECULAR SCIENCE-PURE AND APPLIED CHEMISTRY, 1999, A36 (7-8) :991-1000
[5]   Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren's syndrome patients [J].
Aragona, P ;
Di Stefano, G ;
Ferreri, F ;
Spinella, R ;
Stilo, A .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2002, 86 (08) :879-884
[6]  
Balazs E.A., 1979, US Patent, Patent No. [4141973, #4,141,973]
[7]  
Balazs EA, 1998, WENN GR INT, V72, P325
[8]  
BALAZS EA, 1992, GLYCOSAMINOGLYCANS P, P480
[9]   SODIUM HYALURONATE 0.25-PERCENT USED AS A VEHICLE INCREASES THE BIOAVAILABILITY OF TOPICALLY ADMINISTERED GENTAMICIN [J].
BERNATCHEZ, SF ;
TABATABAY, C ;
GURNY, R .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1993, 231 (03) :157-161
[10]  
Berriaud N., 1998, POLYSACCHARIDES MED, P313